Immunotherapy for cardiovascular disease

The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outco...

Celý popis

Podrobná bibliografia

Vydané v:	European heart journal Ročník 40; číslo 48; s. 3937
Hlavní autori:	Lutgens, Esther, Atzler, Dorothee, Döring, Yvonne, Duchene, Johan, Steffens, Sabine, Weber, Christian
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 21.12.2019
Predmet:	Cardiovascular disease Inflammation Cytokines Novel targets Novel therapies Coronary artery disease
ISSN:	1522-9645, 1522-9645
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!